Correlation Between Purple Biotech and Endonovo Therapeutics

Can any of the company-specific risk be diversified away by investing in both Purple Biotech and Endonovo Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Purple Biotech and Endonovo Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Purple Biotech and Endonovo Therapeutics, you can compare the effects of market volatilities on Purple Biotech and Endonovo Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Purple Biotech with a short position of Endonovo Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Purple Biotech and Endonovo Therapeutics.

Diversification Opportunities for Purple Biotech and Endonovo Therapeutics

0.69

Correlation Coefficient

Purple Biotech  Endonovo Therapeutics

Poor diversification

The 3 months correlation between Purple and Endonovo is 0.69. Overlapping area represents the amount of risk that can be diversified away by holding Purple Biotech and Endonovo Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Endonovo Therapeutics and Purple Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Purple Biotech are associated (or correlated) with Endonovo Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Endonovo Therapeutics has no effect on the direction of Purple Biotech i.e., Purple Biotech and Endonovo Therapeutics go up and down completely randomly.

Pair Corralation between Purple Biotech and Endonovo Therapeutics

Given the investment horizon of 90 days Purple Biotech is expected to under-perform the Endonovo Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Purple Biotech is 1.3 times less risky than Endonovo Therapeutics. The stock trades about -0.18 of its potential returns per unit of risk. The Endonovo Therapeutics is currently generating about -0.04 of returns per unit of risk over similar time horizon. If you would invest  0.12  in Endonovo Therapeutics on September 3, 2024 and sell it today you would lose (0.05) from holding Endonovo Therapeutics or give up 41.67% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Purple Biotech  vs.  Endonovo Therapeutics

Purple Biotech

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Purple Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Endonovo Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Endonovo Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's fundamental indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Purple Biotech and Endonovo Therapeutics

The main advantage of trading using opposite Purple Biotech and Endonovo Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Purple Biotech position performs unexpectedly, Endonovo Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Endonovo Therapeutics will offset losses from the drop in Endonovo Therapeutics' long position.

The idea behind Purple Biotech and Endonovo Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.